nach oben

World Journal of Urology

Erschienen in:

09.11.2019 | Editorial

Developments in oligometastatic hormone-sensitive prostate cancer

verfasst von: Phuoc T. Tran, Piet Ost

Erschienen in: World Journal of Urology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Excerpt

“Suddenly a solitary horseman appeared on the horizon, then another, and another, and then six. In a few moments a whole crowd of solitary horsemen swooped down upon him.” …

Rubin P, Green J (1968) Solitary metastases. C.C. Thomas, Springfield

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10CrossRef

Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R et al (2014) The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol 11(9):549–557CrossRef

Tran PT, Antonarakis ES (2017) Altering the natural history of oligometastatic prostate cancer with local therapies: reality versus illusion. J Oncol Pract 13(1):21–24CrossRef

Chow K, McCoy P, Stuchbery R, Corcoran NM, Hovens CM (2018) Developments in oligometastatic hormone-sensitive prostate cancer. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2542-x CrossRef

Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM (2017) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 14(1):15–25CrossRef

Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J et al (2018) Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2609-8 CrossRef

Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q et al (2011) MicroRNA expression characterizes oligometastasis(es). PLoS One 6(12):e28650CrossRef

Khodarev NN, Pitroda SP, Weichselbaum RR (2015) microRNAs and oligometastasis. Aging (Albany NY) 7(3):146–147CrossRef

10.

Buelens S, De Bleser E, Dhondt B, Verla W, Decaestecker K, Ost P et al (2018) Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2449-6 CrossRef

11.

Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG et al (2016) PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis 19(3):223–230CrossRef

12.

Futterer JJ, Surcel C, van den Bergh R, Borgmann H, Briganti A, Gandaglia G et al (2018) Imaging modalities in synchronous oligometastatic prostate cancer. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2416-2 CrossRef

13.

Pasoglou V, Michoux N, Van Damme J, Van Nieuwenhove S, Halut M, Triqueneaux P et al (2019) Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment. World J Urol 37(12):1. https://doi.org/10.1007/s00345-019-02700-2 CrossRef

14.

Yuan Y, Kishan AU, Nickols NG (2018) Treatment of the primary tumor in metastatic prostate cancer. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2552-8 CrossRef

15.

Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61(1):195–202CrossRef

16.

Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP et al (2004) Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 58(1):3–10CrossRef

17.

Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW et al (2013) Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 24(11):2881–2886CrossRef

18.

Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS, Matthews JH et al (2016) Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol 121(1):98–102CrossRef

19.

Fodor A, Lancia A, Ceci F, Picchio M, Hoyer M, Jereczek-Fossa BA et al (2018) Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2322-7 CrossRef

20.

Patel PH, Chaw CL, Tree AC, Sharabiani M, van As NJ (2018) Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer. World J Urol 37(12):1. https://doi.org/10.1007/s00345-019-02873-w CrossRef

21.

Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES et al (2018) Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World J Urol 37(12):1. https://doi.org/10.1007/s00345-018-2477-2 CrossRef

22.

Triggiani L, Mazzola R, Magrini SM, Ingrosso G, Borghetti P, Trippa F et al (2018) Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol 37(12):1. https://doi.org/10.1007/s00345-019-02717-7 CrossRef

Titel: Developments in oligometastatic hormone-sensitive prostate cancer
verfasst von: Phuoc T. Tran
Piet Ost
Publikationsdatum: 09.11.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 12/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-03009-w

Neu im Fachgebiet Urologie

22.04.2024 | Prostatakarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Developments in oligometastatic hormone-sensitive prostate cancer

Excerpt

Neu im Fachgebiet Urologie

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Urologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2019

Is there enough evidence to support sacral neuromodulation as a viable treatment option in children and adolescents with neurogenic lower urinary tract dysfunction?

Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer

A specific scoring system able to predict the efficacy of the therapy for bladder cancer: why not?

Testosterone replacement therapy is associated with an increased risk of urolithiasis

Comparison between cold knife and laser urethrotomy for urethral stricture: a systematic review and meta-analysis of comparative trials

External validation of a nomogram for the prediction of 10-year life expectancy in candidates for radical prostatectomy

Neu im Fachgebiet Urologie

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Urologie